Acetyl-L-carnitine: From a biological curiosity to a drug for the peripheral nervous system and beyond

Expert Review of Neurotherapeutics

Volumn 13, Issue 8, 2013, Pages 925-936

  Onofrj, Marco ^a   Ciccocioppo, Fausta ^a   Varanese, Sara ^a,b   Di Muzio, Antonio ^a   Calvani, Menotti ^c   Chiechio, Santina ^d   Osio, Maurizio ^e   Thomas, Astrid ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NEW YORK UNIVERSITY   (United States)

^c Sigma Tau SpA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Acetyl L Carnitine; metabotropic glutamate receptors; neuropathic pain; neuropathy; pain

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLCHOLINE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVACECARNINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; PLACEBO; TRANSCRIPTION FACTOR RELA;

ANALGESIC ACTIVITY; ANTIVIRAL THERAPY; AUTONOMIC NEUROPATHY; CENTRAL NERVOUS SYSTEM; DIABETIC NEUROPATHY; DRUG MECHANISM; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; HISTORY OF MEDICINE; HUMAN; MOTOR NEUROPATHY; NERVE FUNCTION; NEUROPATHIC PAIN; NEUROPATHY; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SENSORY NEUROPATHY; UPREGULATION;

ACETYLCARNITINE; ANIMALS; HUMANS; NEURALGIA; NOOTROPIC AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84882785708     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.814930     Document Type: Review

References (145)

1. Tomita M, Sendju Y. Uber die Oxyaminverbindungen welche die Biuret Reaktionen zeigen. III. Spaltung der gamma-Aminobeta-oxybuttersaure in die optisch-Aktiven Komponente. Z Physiol. Chem. 169, 263-277 (1927
2. Gulewitsch W, Krimberg R. Zur Kenntnis der Extractivstoffe der Muskeln. Z Physiol. Chem. 45, 326-328 (1905
3. Kutscher F. Zur Kenntnis des Novains. Z Physiol. Chem. 49, 47-49 (1905
4. Fraenkel G, Blewett M, Coles M BT, a new vitamin of the group and its relation to the folic acid group, and other anti-Anaemia factors. Nature 161, 981-983 (1948
5. Fritz IB. The effects of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta. Physiol. Scand. 34, 367-385 (1955
6. Bremer J. Carnitine in intermediary metabolism. The metabolism of fatty acid esters of carnitine by mitochondria. J. Biol. Chem. 237, 2228-2231 (1962
7. Engel AG, Angelini C Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: A new syndrome. Science 179, 899-902 (1973
8. Angelini C, Vergani L. Primary Myopathic and Systemic Carnitine Deficiency Syndromes: New Concepts from Transport Studies. Ponte Press, Verlags-GmbH, Bochum (1996
9. Scholte HR, de Jonge PC. In: Metabolism, Function and Transport of Carnitine in Health and Disease. Gitzelmann R et al. (Eds.). Schattauer-Verlag, Stuttgart (1987
10. Friedman S, Fraenkel G. Reversible enzymatic acetylation of carnitine. Arch. Biochem. Biophys. 59(2), 491-501 (1955
11. Pande SV. A mitochondrial carnitine acylcarnitine translocase system. Proc. Natl. Acad. Sci. U.S.A. 72(3), 883-887 (1975
12. Weger P. Zur physiologie des carnitins und des acetylcarnitins. Biochim. Z. 287, 424-432 (1936
13. Strack E, Fosterling K. Uber die biologische Wirkung des carnitins und azetylcarnitins. Arch. Exper. Pathol. Pharmakol. 185, 612-662 (1937
14. Dolez al V, Tuc ek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J. Neurochem. 36, 1323-1330 (1981
15. White HL, Scates PW. Acetyl-l-carnitine as a precursor of acetylcholine. Neurochem. Res. 15(6), 597-601 (1990
16. Herzmann C, Whiting SJ, Thomas M, Byrne P, Johnson MA, Youle M Pharmacokinetics of Acetyl-l-carnitine given in single or multiple doses to HIV-1 infected patients with toxic peripheral polyneuropathy. Open AIDS J. 2, 39-42 (2008
17. Goa KL, Brogden A l-Carnitine, a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 34, 1-24 (1987
18. Furlong JH. Acetyl-l-carnitine: Metabolism and applications in clinical practice. Altern. Med. Rev. 1(22), 85-92 (1996
19. Calvani M, Carta A Clues to the mechanism of action of Acetyl-l-carnitine in the central nervous system. Dementia 2, 1-6 (1991
20. Piovesan P, Quatrini G, Pacifici L, Taglialatela G, Angelucci L. Acetyl-l-carnitine restores choline acetyltransferase activity in the hippocampus of rats with partial unilateral fimbria-fornix transection. Int. J. Devl. Neurosci. 13, 13-19 (1995
21. Daily JW, Sachan DS. Choline supplementation alters carnitine homeostasis in humans and guinea pigs. J. Nutr. 125, 1938-1944 (1995
22. Chiechio S, Copani A, De Petris L, Morales ME, Nicoletti F, Gereau RW 4th. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: A possible mechanism for the analgesic effect of l-Acetylcarnitine. Mol. Pain 2, 20 (2006
23. Malone JI, Lowitt S, Corsico N, Orfalian Z. Altered neuroexcitability in experimental diabetic neuropathy: Effect of Acetyl-lcarnitine. Int. J. Clin. Pharmacol. Res. 12(5-6), 237-241 (1992
24. Onofrj M, Fulgente T, Melchionda D et al. l-Acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Int. J. Clin. Pharmacol. Res. 15(1), 9-15 (1995
25. Fernandez E, Pallini R, Lauretti L et al. Levocarnitine acetyl prevents cell death following long-Term section of the vagus nerve in rats. Int. J. Clin. Pharmacol. Res. 12(5-6), 289-297 (1992
26. Gorio A, Di Giulio AM, Tenconi B et al. Peptide alterations in autonomic diabetic neuropathy prevented by Acetyl-l-carnitine. Int. J. Clin. Pharmacol. Res. 12(5-6), 225-230 (1992
27. Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D Acetyl-l-carnitine for symptomatic diabetic neuropathy. Diabetologica 38, 123 (1995
28. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S Acetyl-l-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44, 677-680 (1995
29. Sima AA. Acetyl-l-carnitine in diabetic polyneuropathy: Experimental and clinical data. CNS Drugs 21(1), 13-23; (2007
30. Chiechio S, Copani A, Nicoletti F, Gereau RW 4th. l-Acetylcarnitine: A proposed therapeutic agent for painful peripheral neuropathies. Curr. Neuropharmacol. 4(3), 233-237 (2006
31. Young MJ, Boulton AJM, Macleod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinical population. Diabetalogica 36, 150-154 (1993
32. Merry AC, Kamijo M, Lattimer S et al Long-Term prevention and intervention effects of Acetyl-l-carnitine on diabetic neuropathy in BB/W-rats. Diabetes 43, 108A (1994
33. Chiechio S, Caricasole A, Barletta E et al. l-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol. Pharmacol. 61(5), 989-996 (2002
34. Chiechio S, Copani A, Gereau RW 4th, Nicoletti F Acetyl-l-carnitine in neuropathic pain: Experimental data. CNS Drugs 21(1), 31-38 (2007
35. Chiechio S, Copani A, Zammataro M, Battaglia G, Gereau RW 4th, Nicoletti F. Transcriptional regulation of type-2 metabotropic glutamate receptors: An epigenetic path to novel treatments for chronic pain. Trends Pharmacol. Sci. 31(4), 153-160 (2010
36. Chiechio S, Copani A, Melchiorri D et al. Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain. J. Endocrinol. Invest. 27(6), 171-176 (2004
37. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205-237 (1997
38. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38(10), 1431-1476 (1999
39. Vardi N, Duvoisin R, Wu G, Sterling P. Localization of mGluR6 to dendrites of ON bipolar cells in primate retina. J. Comp. Neurol. 423(3), 402-412 (2000
40. Varney MA, Gereau RW 4th. Metabotropic glutamate receptor involvement in models of acute and persistent pain: Prospects for the development of novel analgesics. Curr. Drug. Targets CNS 1(3), 283-296 (2002
41. Saab CY, Wang J, Gu C, Garner KN, Al-Chaer ED. Microglia: A newly discovered role in visceral hypersensitivity? Neuron Glia Biol. 2(4), 271-277 (2006
42. D'Antoni S, Berretta A, Bonaccorso CM et al. Metabotropic glutamate receptors in glial cells. Neurochem. Res. 33(12), 2436-2443 (2008
43. Chiechio S, Nicoletti F. Metabotropic glutamate receptors and the control of chronic pain. Curr. Opin. Pharmacol. 12(1), 28-34 (2012
44. Zammataro M, Chiechio S, Montana MC et al. mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists. Mol. Pain 14, 7 (2011
45. Gerber G, Zhong J, Youn D, Randic M. Group II and group III metabotropic glutamate receptor agonists depress synaptic transmission in the rat spinal cord dorsal horn. Neuroscience 100(2), 393-406 (2000
46. Carlton SM, Du J, Zhou S. Group II metabotropic glutamate receptor activation on peripheral nociceptors modulates TRPV1 function. Brain Res. 1248, 86-95 (2009
47. Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HE. Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 49(1), 206-218 (2005
48. Chiechio S, Zammataro M, Morales ME et al. Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol. Pharmacol. 75(5), 1014-1020 (2009
49. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 99(5), 451-454 (1999
50. Wolffe AP, Matzke MA. Epigenetics: Regulation through repression. Science 15(286), 481-486 (1999
51. Davie JR, Spencer VA. Control of histone modifications. J. Cell. Biochem. 32(33), 141-148 (1999
52. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006
53. Yang XJ, Seto E. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37), 5310-5318 (2007
54. Kurita M, Holloway T, García-Bea A et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15(9), 1245-1254 (2012
55. Sima AA, Calvani M, Mehra M, Amato A; Acetyl-l-carnitine Study Group. Acetyl-lcarnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care 28(1), 89-94 (2005
56. De Grandis D. Acetyl-l-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: A short review. CNS Drugs 21(1), 39-43 (2007
57. Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G. Effect of Acetyl-l-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J. Peripher. Nerv. Syst. 2(3), 250-252 (1997
58. Hart AM, Wilson AD, Mantovani C et al. Acetyl-l-carnitine: A pathogenesis based treatment for HIV-Associated antiretroviral toxic neuropathy. AIDS 18(11), 1549-1560 (2004
59. Gambi D, Onofrj M, Calvani M et al. Neurophysiological studies of l-Acetylcarnitine administration in man. Drugs Exp. Clin. Res. 15(9), 435-446 (1989
60. Bodis-Wollner I. Physiological effects of Acetyl-Levo-carnitine in the central nervous system. Int. J. Clin. Pharmacol. Res. 10(1-2), 109-114 (1990
61. Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr. Med. Res. Opin. 11(10), 638-647 (1990
62. Hudson S, Tabet N. Acetyl-l-carnitine for dementia. Cochrane Database Syst. Rev. 2, 3158 (2003
63. Passeri M, Cucinotta D, Bonati PA, Iannuccelli M, Parnetti L, Senin U. Acetyl-l-carnitine in the treatment of mildly demented elderly patients. Int. J. Clin. Pharmacol. Res. 10(1-2), 75-79 (1990
64. Sinforiani E, Iannuccelli M, Mauri M et al. Neuropsychological changes in demented patients treated with Acetyl-l-carnitine. Int. J. Clin. Pharmacol. Res. 10(1-2), 69-74 (1990
65. Spagnoli A, Lucca U, Menasce G et al. Long-Term Acetyl-l-carnitine treatment in Alzheimer's disease. Neurology 41(11), 1726-1732 (1991
66. Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: A part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin. Neuropharmacol. 26(5), 239-251 (2003
67. Thal LJ, Carta A, Clarke WR et al. A one-year multicenter placebo-controlled study of Acetyl-l-carnitine in patients with Alzheimer's disease. Neurology 47(3), 705-711 (1996
68. Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl l-carnitine slows decline in younger patients with Alzheimer's disease: A reanalysis of a double-blind, placebocontrolled study using the trilinear approach. Int Psychogeriatr 10(2), 193-203 (1998
69. Montgomery SA, Thal LJ, Amrein R. Meta-Analysis of double blind randomized controlled clinical trials of Acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 18(2), 61-71 (2003
70. Onofrj M, Bodis-Wollner I, Calvani M. Effect of L-Acetyl carnitine HCl on rat steady-state visual evoked potentials. Comparison with l-carnitine. Drugs Exp. Clin. Res. 13(1), 5-13 (1987
71. Onofrj M, Ghilardi MF, Faricelli A, Bodis-Wollner I, Calvani M. Effect of levo-Acetylcarnitine on P300-like potentials of the normal monkey. Drugs Exp. Clin. Res. 13(7), 407-415 (1987
72. Siliprandi N, Siliprandi D, Ciman M. Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. Biochem. J. 96(3), 777-780 (1965
73. Amenta F, Ferrante F, Lucreziotti R, Ricci A, Ramacci MT. Reduced lipofuscin accumulation in senescent rat brain by long-Term Acetyl-l-carnitine treatment. Arch. Gerontol. Geriatr. 9(2), 147-153 (1989
74. Ramacci MT, De Rossi M, Lucreziotti MR, Mione MC, Amenta F. Effect of long-Term treatment with Acetyl-l-carnitine on structural changes of ageing rat brain. Drugs Exp. Clin. Res. 14(9), 593-601 (1988
75. Fernandez E, Pallini R, Gangitano C et al. Effects of l-carnitine, l-Acetylcarnitine and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol. Res. 11(1), 57-62 (1989
76. Pettorossi VE, Brunetti O, Carobi C, Della Torre G, Grassi S. l-Acetylcarnitine enhances functional muscle re-innervation. Drugs Exp. Clin. Res. 17(2), 119-125 (1991
77. De Angelis C, Scarfò C, Falcinelli M, Reda E, Ramacci MT, Angelucci L. Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve injury. Int. J. Clin. Pharmacol. Res. 12(5-6), 269-279 (1992
78. De Simone R, Aloe L, Ferraris L, Ramacci MT. Levocarnitine acetyl treatment promotes iris reinnervation following 6-hydroxydopamine-induced noradrenergic denervation in rats. Int. J. Clin. Pharmacol. Res. 12(5-6), 281-287 (1992
79. Tenconi B, Donadoni L, Germani E et al. Intraspinal degenerative atrophy caused by sciatic nerve lesions prevented by Acetyl-lcarnitine. Int. J. Clin. Pharmacol. Res. 12(5-6), 263-267 (1992
80. Mezzina C, De Grandis D, Calvani M, Marchionni A, Pomes A. Idiopathic facial paralysis: New therapeutic prospects with Acetyl-l-carnitine. Int. J. Clin. Pharmacol. Res. 12(5-6), 299-304 (1992
81. Pettorossi VE, Draicchio F, Fernandez E, Pallini R. The influence of l-Acetylcarnitine on reinnervation of the oculomotor nerve. Int. J. Clin. Pharmacol. Res. 13(3), 193-199 (1993
82. De Angelis C, Scarfò C, Falcinelli M et al. Acetyl-l-carnitine prevents age-dependent structural alterations in rat peripheral nerves and promotes regeneration following sciatic nerve injury in young and senescent rats. Exp. Neurol. 128(1), 103-114 (1994
83. Hart AM, Wiberg M, Youle M, Terenghi G. Systemic Acetyl-l-carnitine eliminates sensory neuronal loss after peripheral axotomy: A new clinical approach in the management of peripheral nerve trauma. Exp. Brain Res. 145(2), 182-189 (2002
84. McKay-Hart A, Wiberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic Acetyl-l-carnitine treatment. Neurosci. Lett. 334(3), 181-185 (2002
85. Wilson AD, Hart A, Brannstrom T, Wiberg M, Terenghi G. Primary sensory neuronal rescue with systemic Acetyl-lcarnitine following peripheral axotomy. A dose-response analysis. Br. J. Plast. Surg. 56(8), 732-739 (2003
86. Wilson AD, Hart A, Brännström T, Wiberg M, Terenghi G. Delayed Acetyl-lcarnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury. J. Plast. Reconstr. Aesthet. Surg. 60(2), 114-118 (2007
87. Wilson AD, Hart A, Wiberg M, Terenghi G. Acetyl-l-carnitine increases nerve regeneration and target organ reinnervation -A morphological study. J. Plast. Reconstr. Aesthet. Surg. 63(7), 1186-1195 (2010
88. Di Giulio AM, Gorio A, Bertelli A, Mantegazza P, Ferraris L, Ramacci MT. Acetyl-l-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals. Int. J. Clin. Pharmacol. Res. 12(5-6), 243-246 (1992
89. Ido Y, McHowat J, Chang KC et al. Neural dysfunction and metabolic imbalances in diabetic rats: Prevention by Acetyl-l-carnitine. Diabetes 43, 1469-1477 (1994
90. Sima AA, Ristic H, Merry A et al. The primary preventive and secondary interventionary effects of Acetyl-l-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J. Clin. Invest. 97, 1900-1907 (1996
91. Stevens MJ, Lattimer SA, Feldman EL et al. Acetyl-l-carnitine deficiency as a cause of altered nerve myo-inositol content, Na-/K-ATPase activity and motor conduction velocity in the streptozotocin diabetic rat. Metabolism 45, 865-872 (1996
92. Scarpini E, Doneda P, Pizzul S et al. L-carnitine and Acetyl-l-carnitine in human nerves from normal and diabetic subjects. J. Peripher. Nerv. Syst. 1(2), 157-163 (1996
93. Ebeling P, Tuominen JA, Arenas J, Garcia Benayas C, Koivisto VA. The association of Acetyl-l-carnitine with glucose and lipid metabolism in human muscle in vivo: The effect of hyperinsulinemia. Metabolism 46(12), 1454-1457 (1997
94. Giancaterini A, De Gaetano A, Mingrone G et al. Acetyl-l-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 49(6), 704-708 (2000
95. Evans JD, Jacobs TF, Evans EW. Role of Acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy. Ann. Pharmacother. 42(11), 1686-1691 (2008
96. Gadaleta MN, Petruzzella V, Daddabbo L et al. Mitochondrial DNA transcription and translation in aged rat. Effect of Acetyl-l-carnitine. Ann. N Y Acad. Sci. 717, 150-160 (1994
97. Gadaleta MN, Cormio A, Pesce V, Lezza AM, Cantatore P. Aging and mitochondria. Biochimie 80(10), 863-870 (1998
98. Pisano C, Pratesi G, Laccabue D et al. Paclitaxel and cisplatin-induced neurotoxicity: A protective role of Acetyl-l-carnitine. Clin. Cancer Res. 9(15), 5756-5767 (2003
99. Bianchi G, Vitali G, Caraceni A et al. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral Acetyl-l-carnitine. Eur. J. Cancer 41(12), 1746-1750 (2005
100. Ghirardi O, Lo Giudice P, Pisano C et al. Acetyl-l-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 25(4), 2681 (2005
101. Ghirardi O, Vertechy M, Vesci L et al. Chemotherapy-induced allodynia: Neuroprotective effect of Acetyl-l-carnitine. In Vivo 19(3), 631-637 (2005
102. Flatters SJ, Xiao WH, Bennett GJ. Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett. 397(3), 219-223 (2006
103. Vanotti A, Osio M, Mailland E, Nascimbene C, Capiluppi E, Mariani C. Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. CNS Drugs 21(1), 3-12; (2007
104. Mancinelli A, D'Iddio S, Bisonni R, Graziano F, Lippe P, Calvani M. Urinary excretion of l-carnitine and its short-chain Acetyl-l-carnitine in patients undergoing carboplatin treatment. Cancer Chemother. Pharmacol. 60(1), 19-26 (2007
105. Xiao WH, Bennett GJ. Chemotherapyevoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by Acetyl-l-carnitine. Pain 135(3), 262 (2008
106. Virmani MA, Biselli R, Spadoni A et al. Protective actions of l-carnitine and Acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res. 32(6), 383-389 (1995
107. Famularo G, Moretti S, Marcellini S et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 11(2), 185-190 (1997
108. Famularo G, De Simone C. Treatment with Acetyl-l-carnitine has the potential to improve the clinical course of painful peripheral neuropathies in HIV-positive patients. J. Peripher. Nerv. Syst. 3(3), 227-229 (1998
109. Youle M. Acetyl-l-carnitine in HIV-Associated antiretroviral toxic neuropathy. CNS Drugs 21(1), 25-30 (2007
110. Herzmann C, Johnson MA, Youle M. Long-Term effect of Acetyl-l-carnitine for antiretroviral toxic neuropathy. HIV Clin. Trials 6(6), 344-350 (2005
111. Osio M, Muscia F, Zampini L et al. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: An open label study. J. Peripher. Nerv. Syst. 11(1), 72-76 (2006
112. Ferraresi R, Troiano L, Roat E et al. Protective effect of Acetyl-l-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett. 580(28-29), 6612-6616 (2006
113. Valcour V, Yeh TM, Bartt R et al. AIDS Clinical Trials Group (ACTG) 5157 protocol team. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitorassociated neuropathy in HIV infection. HIV Med. 10(2), 103-110 (2009
114. De Grandis D, Minardi C. Acetyl-l-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-Term, randomised, double-blind, placebo-controlled study. Drugs R D. 3, 223-231 (200
115. Youle M, Osio M; ALCAR Study Group. A double-blind, parallel-group, placebocontrolled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 8(4), 241-250 (2007
116. Ghelardini C, Galeotti N, Calvani M, Mosconi L, Nicolai R, Bartolini A. Acetyl-l-carnitine induces muscarinic antinociception in mice and rats. Neuropharmacology 43(7), 1180-1187 (2002
117. Di Cesare Mannelli L, Ghelardini C, Calvani M et al. Neuroprotective effects of Acetyl-l-carnitine on neuropathic pain and apoptosis: A role for the nicotinic receptor. J. Neurosci. Res. 87, 200-207 (2009
118. Vivoli E, Di Cesare Mannelli L, Salvicchi A et al. Acetyl-l-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience 167(4), 1168-1174 (2010
119. Malaguarnera M. Carnitine derivatives: Clinical usefulness. Curr. Opin. Gastroenterol. 28(2), 166-176 (2012
120. Zhou P, Chen Z, Zhao N et al. Acetyl-lcarnitine attenuates homocysteine-induced Alzheimer-like histopathological and behavioral abnormalities. Rejuvenation Res. 14(6), 669-679 (2011
121. Jiang X, Tian Q, Wang Y et al. Acetyl-lcarnitine ameliorates spatial memory deficits induced by inhibition of phosphoinositol-3 kinase and protein kinase C. J. Neurochem. 118(5), 864-878 (2011
122. Ruggenenti P, Cattaneo D, Loriga G et al. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: Effects of Acetyl-lcarnitine therapy. Hypertension 54(3), 567-574 (2009
123. McLeod JG. Investigation of peripheral neuropathy. J. Neurol. Neurosurg. Psichiatry. 58, 274-283 (1995
124. Head KA. Peripheral neuropathy: Pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 11(4), 294-329 (2006
125. Bosch EP, Pelhan RW, Rasool CB. Animal models of alcoholic neuropathy: Morphologic, electrophysiologic and biochemical findings. Muscle Nerve 2, 133-144 (1979
126. Di Cesare Mannelli L, Ghelardini C, Calvani M et al. Protective effect of Acetyl-l-carnitine on the apoptotic pathway of peripheral neuropathy. Eur. J. Neurosc. 26, 820-827 (2007
127. Mansour HH. Protective role of carnitine ester against radiation-induced oxidative stress in rats. Pharmacol. Res. 54, 165-171 (2006
128. Merskey H. Clarifying definition of neuropathic pain. Pain 96, 408-409 (2002
129. Ossipov MH. Growth factors and neuropathic pain. Curr. Pain Headache Rep. 15, 185-192 (2011
130. Boucher TJ, McMahon SB. Neurotrophic factors and neuropathic pain. Curr. Opin. Pharmacol. 1, 66-72 (2001
131. Waxman SG. The molecular pathophysiology of pain: Abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain 6, 133-140 (1999
132. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 9, 1765-1769 (2000
133. Ramer MS, French GD, Bisby MA. Wallerian degeneration is required for both neuropathic pain and sympathetic sprouting into the DRG. Pain 72, 71-78 (1997
134. Sah D, Ossipov M, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat. Rev. Drug Discov. 2, 460-472 (2003
135. Pezet S, McMahon SB. Neurotrophins: Mediators and modulators of pain. Annu. Rev. Neurosci. 29, 507-538 (2006
136. Levin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 6, 1903-1912 (1994
137. Piovesan P, Pacifici L, Taglialatela G, Ramacci MT, Angelucci L. Acetyl-l-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 633, 77-82 (1994
138. Foreman PJ, Perez-Polo JR, Angelucci L, Ramacci MT, Taglialatela G. Effect of Acetyl-l-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 117-133 (1995
139. Galeotti N, Bartolini A, Calvani M, Nicolai R, Ghelardini C. Acetyl-l-carnitine requires phospholipase C-IP3 pathway activation to induce antinociception. Neuropharmacology 472, 286-294 (2004
140. Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. 0.025% Capsaicin Gel for the treatment of painful diabetic neuropathy: A randomized, double-blind, crossover, placebo-controlled trial. Pain Pract. (2012). doi: 10.1111/papr.12013
141. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane. Database Syst. Rev. 21, 1 (2009
142. Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.12, 9 (2012
143. Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.15, 8 (2012
144. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7(9), 507-517 (2011
145. Magy L, Mathis S, Vallat JM. Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies. Curr. Opin. Crit. Care 17(2), 101-105 (2011